Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vedanta Biosciences Enrolls First Patient in Phase 3 RESTORATiVE303 Study of VE303
Details : VE303 is a potential first-in-class live biotherapeutic product candidate consisting of a defined bacterial consortium designed for the prevention of recurrent Clostridioides difficile infection.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 21, 2024
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 05, 2023
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : AXA IM Alts
Deal Size : $106.5 million
Deal Type : Financing
Details : The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activitie...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
April 25, 2023
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : AXA IM Alts
Deal Size : $106.5 million
Deal Type : Financing
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase II
Recipient : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VE202 is a first-in-class, orally administered, investigational live biotherapeutic product (LBP) consortium consisting of 16 strains of bacteria, which is investigated for the treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : VE202,Vancomycin Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase II
Recipient : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 24, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE202
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : VE202
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recur...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : VE303
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PureTech Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
Details : Vedanta intends to use the proceeds to fund a Phase 2 study of VE202 in inflammatory bowel disease (IBD), which it plans to initiate in 2021.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Undisclosed
December 01, 2021
Lead Product(s) : VE202
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing